Cocrystal Agreement for NXP001 with Newsummit Biopharma & £2.5m Payment plus Double Digit Royalty on Sales

Cambridge, UK - 15th December 2017

Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, announces it has entered into an addendum to the Cocrystallisation Service Agreement dated 30 October 2015 (“Original Agreement”) with Shanghai Newsummit Biopharma Group Company Limited (“Newsummit”) to include a license to NXP001, for the Chinese market only.

Download News

Back to all News